At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 262 enrolled
Drug / intervention
700 μg Dexamethasone +1 moredrug
Likely dose
700 μg Dexamethasonefrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy Study of Dexamethasone in the Treatment of Patients With Macular Edema Following Retinal Vein Occlusion (RVO)
In Brief
A Phase 3 clinical trial evaluating 700 μg Dexamethasone and Sham for Macular Edema. Completed, enrolled 262 participants across 1 site.
Detailed Summary
This study will assess the safety and efficacy of 700 μg dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in patients with macular edema in a 6 month double-blind period versus sham followed by a 2 month open label period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMacular Edema
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 2012
Enrollment StartSep 2012
Primary CompletionMar 2014
Study CompletionMay 2014
TodayJul 2026
First PostedAug 9, 2012
Enrollment StartSep 4, 2012
Primary CompletionMar 31, 2014
Study CompletionMay 20, 2014
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 13.9 years ago
Interventions
700 μg Dexamethasonedrug
700 μg Dexamethasone intravitreal injection in the study eye on Day 1.
Shamother
Sham administered in the study eye on Day 1.